Myocardial Infarction after Long-Term Treatment with a Tyrosine Kinase Inhibitor (TKI) with Anti-VEGF Receptor Activity

TKIs including anti-VEGF receptor activity have been approved for the treatment of patients with radioiodine resistant thyroid carcinomas. For lenvatinib arterial thromboembolic events are listed as adverse events of special interest with lenvatinib. In the phase III study, arterial thromboembolic e...

Descripción completa

Detalles Bibliográficos
Autores principales: Paschke, L., Lincke, T., Mühlberg, K., Lindner, Tom H., Paschke, R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6590543/
https://www.ncbi.nlm.nih.gov/pubmed/31281683
http://dx.doi.org/10.1155/2019/7927450

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6590543/
https://www.ncbi.nlm.nih.gov/pubmed/31281683
http://dx.doi.org/10.1155/2019/7927450

Ejemplares similares